The qualifications of Dr. Cornyn, Epidemiologist are perhaps called into question by these hardy folks:
(Feb 10): Business Insider Article Image Link: A greater horseshoe bat (Rhinolophus FerrumEquinum), a relative of the Rhinolophis sinicus bat species from China that was the origin of the SARS virus.
.
Perhaps Dr. Cornyn hypothesizes that infections are relatively low in Africa for this scientific reason:
Source: https://i.imgur.com/ONxq8wH.jpg
Such impressive political minds in power in the upcoming Texas Killing Fields (Abbott, Cornyn, Cruz).
Ever wondered how germs spread so easily?
This disturbing documentary evidence leaves little if any doubt in the minds of esteemed luminaries that we are here dealing with Obamadust - known to have induced Pizzagate. Trust no one, … save for “Q” !
…and over 300 per day for the last four days… this is shocking news… I can only pray it don’t get that bad here!
March 18, 2020
The US know we are behind in all aspects of dealing with this virus. I feel our future has been forecast and a nationwide lockdown is inevitable… I welcome a nationwide lockdown right now in order to save lives two or more weeks from now. Do we need to see numbers like Italy to be convinced?
I agree. Just taking it day-by-day.
If the microbes don’t kill you, it may be that physicians’ blunt-instrument “cures” just possibly might:
ADVERSE REACTIONS
The following adverse reactions have been identified during post-approval use of PLAQUENIL or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
Cardiac disorders: Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE). PLAQUENIL prolongs the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking PLAQUENIL (see OVERDOSAGE and DRUG INTERACTIONS).
Ear and labyrinth disorders: Vertigo, tinnitus, nystagmus, nerve deafness, deafness.
Eye disorders: Irreversible retinopathy with retinal pigmentation changes (bull’s eye appearance), visual field defects (paracentral scotomas) and visual disturbances (visual acuity), maculopathies (macular degeneration), decreased dark adaptation, color vision abnormalities, corneal changes (edema and opacities) including corneal deposition of drug with or without accompanying symptoms (halo around lights, photophobia, blurred vision).
Gastrointestinal disorders: Nausea, vomiting, diarrhea, and abdominal pain.
General disorders and administration site conditions: Fatigue.
Hepatobiliary disorders: Liver function tests abnormal, hepatic failure acute.
Immune system disorders: Urticaria, angioedema, bronchospasm.
Metabolism and nutrition disorders: Decreased appetite, hypoglycemia, porphyria, weight decreased.
Musculoskeletal and connective tissue disorders: Sensorimotor disorder, skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction.
Nervous system disorders: Headache, dizziness, seizure, ataxia and extrapyramidal disorders such as dystonia, dyskinesia, and tremor have been reported with this class of drugs.
Psychiatric disorders: Affect/emotional lability, nervousness, irritability, nightmares, psychosis, suicidal behavior.
Skin and subcutaneous tissue disorders: Rash, pruritus, pigmentation disorders in skin and mucous membranes, hair color changes, alopecia. Dermatitis bullous eruptions including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), photosensitivity, dermatitis exfoliative, acute generalized exanthematous pustulosis (AGEP). AGEP has to be distinguished from psoriasis, although PLAQUENIL may precipitate attacks of psoriasis. It may be associated with pyrexia and hyperleukocytosis.
Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
.
crikey, have to hand it to these people that work in these laboratories.
How stressful suited up for hours on end and working with deadly pathogens?
Not for me im afraid.
Now that’s the absolute front line of defense!
far out, poor tim mclain.
Was sent all his flight tickets, checkpoint passes etc thought they were off to australia then couldnt get transport to the airport at the last hurdle?
Damn, talk about geed, then f#@ked.
Like to know of any updates how he’s going?
yep, takes special people i think.
Illuminati(ing) indeed
I meant no slant against anyone working for the public good and I hope it wasn’t taken that way. It’s that without research most viruses or illnesses would kill even more without finding treatment or a cure. I agree it does take balls to enter a death zone without a full containment suit.
As at 6.30am on 19 March 2020, there have been 565 confirmed cases of COVID-19 in Australia. There have been 111 new cases since 6.30am yesterday.
| Location | Confirmed cases* |
|---|---|
| Australian Capital Territory | 3 |
| New South Wales | 265 |
| Northern Territory | 0 |
| Queensland | 94 |
| South Australia | 37 |
| Tasmania | 10 |
| Victoria | 121 |
| Western Australia | 35 |
| Total** | 565 |
| * *Note that under National Notifiable Diseases Surveillance System reporting requirements, cases are reported based on their Australian jurisdiction of residence rather than where they were detected. For example, a case reported previously in the NT in a NSW resident is counted in the national figures as a NSW case. | |
| * **Includes Diamond Princess repatriation cases: Qld (3), SA (1), Vic (4), WA (2, including 1 death) |
Case details
Of the 565 confirmed cases in Australia, 46 have recovered and 6 have died from COVID-19.
259 cases were considered to be overseas acquired. Most of the overseas cases were acquired in the USA, Iran, Italy and the UK.
72 cases are contacts of previously confirmed cases.
The likely place of exposure for 206 reported cases is under investigation.
The source of infection for 28 cases is currently unknown.
Further information regarding the epidemiology of cases in Australia is provided in the weekly epidemiology reports.
This hypothetical assertion is getting quite a bit of blowback from the clinical community. Based upon opinion correspondence in The Lancet (03-11-20). Interesting, but without known evidentiary basis.
Here is an informative Medscape article (03-11-20) that discusses ACE2 receptor-expression subjects:
Scientists Seek Answers to Hypertension - COVID-19 Link
.
… through integrating public genomics, epigenomics and transcriptomics data, we examined whether variation of the SARS-CoV2 receptor ACE2 gene expression in different tissues across individuals can explain the differences in infection susceptibility and outcome. Our findings are contrary to the expectation from ACE2 being only a receptor for the virus, instead, its expression level is high in Asian females and young people, those who are known to be less susceptible, and even less inflicted by severe or fatal outcome, while it is low in males, further decrease with age and T2D, those who are most susceptible to bad outcome, suggesting at a population level a negative correlation between ACE2 expression and CovID19 severity and fatality. … Our results established a counter argument against the speculation that high ACE2 is a culprit in CoVID-19 outcome, and on the contrary supports a protective role of high ACE2 expression against SARS-CoV2 fatality.
Source: Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation
(document is a pre-print of a research paper published on March 12, 2020)